Methods of Treating Giardiasis Using FDA-Approved Compounds
Posted Aug 11 2011 8:00pm
Description of Invention: This technology includes a group of at least twenty-nine, diverse, commercially available compounds that are newly identified for activity against Giardia lamblia parasites. At least six of the candidate compounds, Bortezomib, Decitabine, Hydroxocobalamin, Amlexanox, Idarubicin, and Auranofin have preexisting FDA approval for human use for other (non-Giardia) conditions. Another three compounds, Fumagillin, Nitarsone and Carbadox have preexisting approval for veterinary use for non-Giardia conditions. Additional active compounds identified include: Acivicin, Riboflavin butyrate, BTO-1, GW9662, Dinitroph-dfgp, Deserpidine, Tetramethylthiuram disulsulfide, Disulfiram, Mitoxantrone, Ecteinascidin 743, 17-allyaminogeldanamycin, Carboquone and Nocodazole. The anti-Giardial activity of these compounds presents a cost saving opportunity for the rapid development of new, better tolerated treatments for the most prevalent human intestinal parasite infection in the United States and the world.
Applications:
Treatment of Giardia in humans
Treatment of Giardia in animals - dogs and cats
Advantages: These compounds have currently been approved for human and veterinary uses of other indications which provides an opportunity to greatly reduce risk and pre-market investments both in terms of time and costs associated with development and regulatory approval for new Giardia applications including the drug resistant Giardiasis.
Development Status:
Early-stage
Pre-clinical
In vitro data available
Inventors: Wei Zheng (NHGRI) Catherine Chen (NHGRI) Juan J Marugan (NHGRI) Noel T Southall (NHGRI) Christopher P Austin (NHGRI) Osnat Herzberg (University of Maryland Biotechnology Institute) Liudmila Kulakova (University of Maryland) Andrey Galkin (University of Maryland)
Collaborative Research Opportunity: The NHGRI is seeking stateents of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Novel Compounds for Treatment of Giardiasis. For collaboration opportunities, please contact Claire Driscoll, NHGRI, at cdriscol@mail.nih.gov .
For Licensing Information Please Contact: Edward (Tedd) Fenn NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: fennea@mail.nih.gov Phone: 301-435-5031 Fax: 301-402-0220
Description of Invention:
This technology includes a group of at least twenty-nine, diverse, commercially available compounds that are newly identified for activity against Giardia lamblia parasites. At least six of the candidate compounds, Bortezomib, Decitabine, Hydroxocobalamin, Amlexanox, Idarubicin, and Auranofin have preexisting FDA approval for human use for other (non-Giardia) conditions. Another three compounds, Fumagillin, Nitarsone and Carbadox have preexisting approval for veterinary use for non-Giardia conditions. Additional active compounds identified include: Acivicin, Riboflavin butyrate, BTO-1, GW9662, Dinitroph-dfgp, Deserpidine, Tetramethylthiuram disulsulfide, Disulfiram, Mitoxantrone, Ecteinascidin 743, 17-allyaminogeldanamycin, Carboquone and Nocodazole. The anti-Giardial activity of these compounds presents a cost saving opportunity for the rapid development of new, better tolerated treatments for the most prevalent human intestinal parasite infection in the United States and the world.
Applications:
Advantages:
These compounds have currently been approved for human and veterinary uses of other indications which provides an opportunity to greatly reduce risk and pre-market investments both in terms of time and costs associated with development and regulatory approval for new Giardia applications including the drug resistant Giardiasis.
Development Status:
Inventors:
Wei Zheng (NHGRI)
Catherine Chen (NHGRI)
Juan J Marugan (NHGRI)
Noel T Southall (NHGRI)
Christopher P Austin (NHGRI)
Osnat Herzberg (University of Maryland Biotechnology Institute)
Liudmila Kulakova (University of Maryland)
Andrey Galkin (University of Maryland)
Patent Status:
HHS, Reference No. E-211-2010/1
US, Application No. 61/411,509 filed 09 Nov 2010
Relevant Publication:
Collaborative Research Opportunity:
The NHGRI is seeking stateents of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Novel Compounds for Treatment of Giardiasis. For collaboration opportunities, please contact Claire Driscoll, NHGRI, at cdriscol@mail.nih.gov .
For Licensing Information Please Contact:
Edward (Tedd) Fenn
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: fennea@mail.nih.gov
Phone: 301-435-5031
Fax: 301-402-0220
Ref No: 2307
Updated: 08/2011